Succinate dehydrogenase deficiency is associated with decreased 5-hydroxymethylcytosine production in gastrointestinal stromal tumors: Implications for mechanisms of tumorigenesis

Modern Pathology

Volumn 26, Issue 11, 2013, Pages 1492-1497

  Mason, Emily F ^a   Hornick, Jason L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

5 hydroxymethylcytosine; gastrointestinal stromal tumor; KIT; methylation; PDGFRA; succinatedehydrogenase; TET

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SUCCINATE DEHYDROGENASE;

ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; COMPLEX II DEFICIENCY; DNA METHYLATION; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE MUTATION; GENOTYPING TECHNIQUE; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

CELL TRANSFORMATION, NEOPLASTIC; CYTOSINE; DNA MUTATIONAL ANALYSIS; DOWN-REGULATION; ELECTRON TRANSPORT COMPLEX II; EXONS; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MUTATION; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SUCCINATE DEHYDROGENASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84887086564     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.86     Document Type: Article

References (43)

1. Marrari A, Wagner AJ, Hornick JL. Predictors of response to targeted therapies for gastrointestinal stromal tumors. Arch Pathol Lab Med 2012;136: 483-489.
2. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007;369:1731-1741. (Pubitemid 46778870)
3. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347: 472-480. (Pubitemid 34879334)
4. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-1338. (Pubitemid 44528723)
5. Liegl-Atzwanger B, Fletcher JA, Fletcher CDM. Gastrointestinal stromal tumors. Virchows Arch 2010;456:111-127.
6. Prakash S, Sarran L, Socci N, et al. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol 2005;27:179-187. (Pubitemid 40604837)
7. Agaram NP, Laquaglia MP, Ustun B, et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 2008;14:3204-3215.
8. Agaimy A, Terracciano LM, Dirnhofer S, et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol 2009; 62:613-616.
9. Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008;47:853-859.
10. Hostein I, Faur N, Primois C, et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol 2010;133:141-148.
11. Wang JH, Lasota J, Miettinen M. Succinate dehydrogenase subunit B (SDHB) is expressed in neurofibromatosis 1-associated gastrointestinal stromal tumors (GISTs): implications for the SDHB expression based classification of GISTs. J Cancer 2011;2:90-93.
12. Barletta JA, Hornick JL. Succinate dehydrogenasedeficient tumors: diagnostic advances and clinical implications. Adv Anat Pathol 2012;19:193-203.
13. Pasini B, McWhinney SR, Bei T, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 2008;16: 79-88. (Pubitemid 350284184)
14. Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA 2011;108:314-318.
15. Italiano A, Chen CL, Sung YS, et al. SDHA loss of function mutations in a subset of young adult wildtype gastrointestinal stromal tumors. BMC Cancer 2012;12:408.
16. Pantaleo MA, Astolfi A, Indio V, et al. SDHA loss-offunction mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. J Natl Cancer Inst 2011;103: 983-987.
17. Pantaleo MA, Nannini M, Astolfi A, et al. A distinct pediatric-type gastrointestinal stromal tumor in adults: potential role of succinate dehydrogenase subunit A mutations. Am J Surg Pathol 2011;35:1750-1752.
18. Wagner AJ, Remillard SP, Zhang YX, et al. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod Pathol 2013;26:289-294.
19. Oudijk L, Gaal J, Korpershoek E, et al. SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. Mod Pathol 2013;26:456-463.
20. Dwight T, Benn DE, Clarkson A, et al. Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors. Am J Surg Pathol 2013;37:226-233.
21. Miettinen M, Killian JK, Wang ZF, et al. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am J Surg Pathol 2013;37:234-240.
22. Doyle LA, Nelson D, Heinrich MC, et al. Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study. Histopathology 2012;61:801-809.
23. Gao J, Dang Y, Sun N, et al. C-KIT mutations were closely associated with the response to imatinib in Chinese advanced gastrointestinal stromal tumor patients. Med Oncol 2012;29:3039-3045.
24. Pollard PJ, Brière JJ, Alam NA, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005;14:2231-2239. (Pubitemid 41418022)
25. Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005;7:77-85. (Pubitemid 40126384)
26. Xiao M, Yang H, Xu M, et al. Inhibition of a-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 2012;26:1326-1338.
27. Tan L, Shi YG. Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development 2012;139:1895-1902.
28. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2012;18:553-567.
29. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2012;17:510-522.
30. Yang H, Liu Y, Bai F, et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013;32: 663-669.
31. Lian CG, Xu Y, Ceol C, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012;150:1135-1146.
32. Pansuriya TC, van Eijk R, d'Adamo P, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011;43:1256-1261.
33. Shih AH, Abdel-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012;12:599-612.
34. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-773.
35. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011;224: 334-343.
36. Borger DR, Zhu AX. IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications. Expert Rev Anticancer Ther 2012;12: 543-546.
37. Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 2005;5:857-866. (Pubitemid 41746030)
38. Ishii T, Yasuda K, Akatsuka A. A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. Cancer Res 2005;65: 203-209. (Pubitemid 40070811)
39. Kaelin WG. Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb Symp Quant Biol 2011;76:335-345.
40. Cervera AM, Bayley J-P, Devilee P, et al. Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells. Mol Cancer 2009;8:89.
41. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468:839-843.
42. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17: 225-234.
43. Oermann EK, Wu J, Guan K-L, et al. Alterations of metabolic genes and metabolites in cancer. Semin Cell Dev Biol 2012;23:370-380.